FDA Approves Infliximab Biosimilar for Subcutaneous Use Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease. https://t.co/oTGm16k6Uo https://t.co/tSysmriP7q https://t.co/TIZc8rxwxM

JAMA Review of Knee Pain: - 5% PCP visits for knee pain: - Knee #OA: 654 mill worldwide, mostly >45 yrs age - Patellofemoral OA: < 40 yrs age; Sx: ant knee pain w/ squat - Meniscal tears: 12% adults < 40 yrs; dx by McMurray test & joint line tenderness https://t.co/AKVFXjY0D8 https://t.co/GpBxA2rdLP

JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs. https://t.co/07PrYidnt9 https://t.co/qWM9N68hZ1

Check out the latest therapeutic update for axSpA in this video series dedicated to creating a better understanding of treatment goals.https://t.co/8zFMwt5Q7g https://t.co/tc9txlCgw8

PMR Mythbusters: PMR Gets 100% Better Within 72 hours https://t.co/S7PWlNoQez https://t.co/CN469rzGVl

Cardiovascular and VTE Risk w/JAKi Treatment of Skin Disorders A JAMA systematic review and meta-analysis has shown the use of JAKi in immune-mediated inflammatory skin diseases was not associated w/ increased risk of all-cause mortality, MACE, or VTE. https://t.co/XYAeLnFvHr https://t.co/tGRNEUEZj9

Optimal Management of DQT The treatment of DQT was examined by systematic review in JAMA, suggesting that local corticosteroid injection + a thumb spica immobilization was associated w/significant pain-relieving and functional benefits. https://t.co/1437g9ylZy https://t.co/TTlF28oa1S

Study of LATE-onset RA (>65y), shows DMARD initiation is low in LORA; despite current clinical practice guidelines recommending early aggressive Rx. Among 3,373 LORA pts (age77 yrs), only 29% initiated on a DMARD (28.9%). https://t.co/bWHaiiSMVl https://t.co/NmrDeG8UPW

Fast track clinics -the future of #PMR care? As the month dedicated to PMR draws to a close, we begin to look to the future, and what the ideal management of PMR looks like. https://t.co/F4oRPnKWhe https://t.co/1yoUNaQqW5

Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108). - 27% flared at 2/3 dose - 20% at 1/2 dose - 27% at 1/3 dose - 25% w/ discontinuation WHY WOULD YOU DO THIS? I DONT! https://t.co/mIJKaK3LK5 https://t.co/SMGJVfepTl

256 Early RA pt cohort followed 10yrs showed SDAI sustained remission(n 48) had less 10 yr Xray progression (mTSS 4.06), vs sustained LDA (14.6) or MDA/HDA (21.04). Sustained remission pts were younger, lower HAQ & mTSS scores; less need for GC & bDMARDs https://t.co/92L7RTCx82 https://t.co/4uZBydcfRM

Steroid (GC) use is increasing - Claims data from (US, Taiwan, Denmark; n=54,630,437; 2009-2018), GC use increased from 6.4 to 7.7% USA, 16.6 to 18.7% Taiwan, & 1.7 to 2.9% Denmark. Most Rx by PCP to healthy adults; 20-25% Rx for URI. https://t.co/GkQR0hcys1 https://t.co/5fpBv2Kyo8